Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Operations (2016 - 2025)

Sunshine Biopharma's Cash from Operations history spans 14 years, with the latest figure at 1616006.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 52.54% year-over-year to 1616006.0; the TTM value through Dec 2025 reached 5331073.0, up 57.44%, while the annual FY2025 figure was 5331073.0, 57.44% up from the prior year.
  • Cash from Operations reached 1616006.0 in Q4 2025 per SBFM's latest filing, down from 727800.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 297355.0 in Q1 2021 to a low of 4577784.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 1685422.45, with a median of 1330392.5 recorded in 2022.
  • Peak YoY movement for Cash from Operations: crashed 858.16% in 2021, then surged 72.18% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 312113.0 in 2021, then tumbled by 619.81% to 2246612.0 in 2022, then decreased by 19.72% to 2689676.0 in 2023, then fell by 26.6% to 3405260.0 in 2024, then soared by 52.54% to 1616006.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Cash from Operations are 1616006.0 (Q4 2025), 727800.0 (Q3 2025), and 1273432.0 (Q2 2025).